Click on headlines below to download research
Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent capital markets day (CMD) highlighted the strong positioning of its three key franchises.…
Reported 9M20 numbers highlight continual strength in sales across key franchises and ongoing margin expansion. ROVI reported operating revenue of €302.1m…
Laboratorios Farmacéuticos ROVI reported H120 operating revenue of €191.1m (+8% y-o-y), driven by strong growth in heparins (+23% to €104.0m)…
Laboratorios Farmacéuticos ROVI (ROVI) reported Q120 operating revenue of €101.0m (+23% y-o-y), driven by strong growth both in the speciality…
ROVI is a profitable speciality healthcare company that markets ~40 proprietary and in-licensed products across nine core franchises, mainly in its domestic…
Laboratorios Farmacéuticos ROVI has reported a strong set of FY19 results, with all pillars of the business contributing to revenue growth of 26%…
Following Laboratorios Farmacéuticos ROVI’s (ROVI’s) recent investor day, we have reviewed our near-term forecasts. Specifically, we…
Laboratorios Farmacéuticos ROVI (ROVI) has reported operating revenue of €270.8m (+24% y-o-y) for the first nine months of FY19 (9M19), driven…
Interim results highlight the momentum at Laboratorios Farmacéuticos ROVI, as both H119 operating revenue (21% y-o-y to €177.5m) and EBITDA…